Profile data is unavailable for this security.
About the company
3SBio Inc is an investment holding company principally engaged in the development, production, marketing and sale of biopharmaceutical products. The Company's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The Company is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The Company's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)10.21bn
- Net income in HKD2.65bn
- Incorporated2006
- Employees6.27k
- Location3SBio IncNo. 3 A1, Road 10Shenyang Economy & TechnologyDevelopment ZoneSHENYANG 110027ChinaCHN
- Phone+86 2 425811820
- Fax+86 2 425811821
- Websitehttps://www.3sbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical Group Ltd | 8.00bn | 990.58m | 30.89bn | 6.82k | 29.55 | 3.62 | 22.27 | 3.86 | 0.4027 | 0.4027 | 3.24 | 3.29 | 0.5845 | 2.20 | 2.81 | 1,214,764.00 | 7.24 | 8.74 | 9.93 | 12.42 | 81.00 | 78.53 | 12.39 | 15.60 | 1.57 | 4.72 | 0.1453 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| Xuanzhu Biopharmaceutical Co Ltd | 35.97m | -626.15m | 34.44bn | 197.00 | -- | 36.18 | -- | 957.68 | -1.21 | -1.21 | 0.0694 | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | 41.02 | -- | -1,740.97 | -- | 1.10 | -- | 0.0013 | -- | 103,672.40 | -- | -85.13 | -- | -- | -- |
| China Medical System Holdings Ltd | 8.85bn | 1.86bn | 36.20bn | 6.10k | 19.31 | 1.89 | 16.86 | 4.09 | 0.7684 | 0.7684 | 3.66 | 7.85 | 0.4239 | 3.14 | 6.12 | 1,440,449.00 | 8.85 | 16.35 | 9.88 | 18.70 | 71.47 | 75.03 | 20.88 | 32.20 | 5.28 | -- | 0.0417 | 40.16 | -6.79 | 4.22 | -32.54 | -3.75 | 6.01 | -2.60 |
| 3SBio Inc | 10.21bn | 2.65bn | 58.68bn | 6.27k | 21.50 | 2.97 | 17.73 | 5.75 | 1.08 | 1.08 | 4.13 | 7.78 | 0.3799 | 1.54 | 6.97 | 1,831,129.00 | 10.46 | 7.95 | 15.09 | 10.32 | 85.37 | 83.73 | 27.54 | 22.68 | 2.12 | -- | 0.0899 | -- | 16.53 | 11.36 | 34.93 | 16.51 | 14.65 | -- |
| WuXi XDC Cayman Inc | 5.73bn | 1.49bn | 78.18bn | 2.27k | 54.06 | 8.93 | 47.66 | 13.65 | 1.15 | 1.15 | 4.41 | 6.96 | 0.5687 | 21.58 | 3.31 | 2,805,584.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 16 Jan 2026 | 150.52m | 5.93% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 72.33m | 2.85% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 68.70m | 2.71% |
| BlackRock Fund Advisorsas of 27 Aug 2025 | 64.25m | 2.53% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 48.55m | 1.91% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 36.62m | 1.44% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 35.90m | 1.41% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 35.83m | 1.41% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 33.04m | 1.30% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 19.25m | 0.76% |
